文献速递真菌感染

泊沙康唑在儿童恶性肿瘤及造血干细胞移植中的应用:达到治疗浓度的给药方案

Posaconazole in paediatric malignancy and haematopoietic stem cell transplant: dosing to achieve therapeutic concentration.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

该系统综述检索截至2023年5月的文献,纳入24项儿童恶性肿瘤或造血干细胞移植后泊沙康唑给药研究。口服混悬液即使高剂量(14-23 mg/kg/日)预防目标浓度达标率仍低(12%-78%),而缓释片、粉末口服混悬液和静脉制剂达标率较高,所有剂型耐受性良好。

要点

  • 口服混悬液预防达标率低(12%-78%),受胃pH和食物摄入显著影响。
  • 缓释片58%-94%达标,多使用较低剂量4-12 mg/kg/日(最大300 mg/日)。
  • 静脉制剂预防达标率最高(81%-90%),剂量6-10 mg/kg/日(最大400 mg/日)。

核心结论

  • 免疫受损儿童的泊沙康唑所需剂量因剂型而异,静脉输注达标率最高,其次为缓释片和粉末口服混悬液,口服混悬液即使日剂量较高达标率仍低。

研究设计与样本

  • 系统综述,2023年5月检索Cochrane、Embase、MEDLINE和PubMed数据库,纳入报告恶性肿瘤或造血干细胞移植后儿童泊沙康唑给药且报告目标血清浓度达标情况的研究,共24项。

主要发现

  • 18项口服混悬液研究一致报告预防目标浓度(≥0.7 µg/mL)达标率低,为12%-78%,尽管日剂量高达14-23 mg/kg/日(最大1200 mg/日)。
  • 目标达标率受胃pH和食物摄入显著影响。
  • 6项缓释片研究报告58%-94%达到≥0.7 µg/mL,多数使用较低剂量4-12 mg/kg/日(最大300 mg/日)。
  • 1项粉末口服混悬液研究报告67%-100%达到目标浓度,剂量为6 mg/kg/日(最大300 mg/日)。
  • 静脉制剂预防目标达标率为81%-90%,剂量为6-10 mg/kg/日(最大400 mg/日)。

关键数值与推荐

  • 口服混悬液预防目标浓度为≥0.7 µg/mL,达标率12%-78%,日剂量14-23 mg/kg/日(最大1200 mg/日)。
  • 缓释片达标率58%-94%(目标≥0.7 µg/mL),多数剂量4-12 mg/kg/日(最大300 mg/日)。
  • 粉末口服混悬液达标率67%-100%,剂量6 mg/kg/日(最大300 mg/日)。
  • 静脉制剂预防达标率81%-90%,剂量6-10 mg/kg/日(最大400 mg/日)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Posaconazole is increasingly used for the treatment and prophylaxis of invasive fungal infections in immunocompromised children. We aimed to review evidence for paediatric posaconazole dosing regimens focusing on attainment of target concentrations and frequency of adverse effects. METHODS: In May 2023, the Cochrane, Embase, MEDLINE and PubMed databases were searched for articles reporting posaconazole dosing in children with malignancy or post-haematopoietic stem cell transplantation. Studies reporting the attainment of target serum concentrations were included. RESULTS: Overall, 24 studies were included. Eighteen studies of the oral suspension consistently reported poor attainment of target concentrations for prophylaxis (≥0.7 µg/mL, 12%-78%) despite high daily doses of 14-23 mg/kg/day (max. 1200 mg/day). Target attainment was significantly affected by gastric pH and food intake. Six studies of the delayed-release tablet (DRT) reported 58%-94% achieved concentrations ≥0.7 µg/mL, with the majority using lower doses of 4-12 mg/kg/day (max. 300 mg/day). Similarly, one study of powder for oral suspension found 67%-100% achieved target concentrations with a dose of 6 mg/kg/day (max. 300 mg/day). As expected, the IV formulation had high attainment of prophylaxis targets (81%-90%) with 6-10 mg/kg/day (max. 400 mg/day). All formulations were well tolerated, and no relationship between adverse effects and posaconazole concentrations was identified. CONCLUSIONS: The required posaconazole dose in immunocompromised children varies depending on the formulation. The IV infusion had the highest attainment of therapeutic concentration followed by the DRT and powder for suspension. By contrast, the oral suspension had low attainment of target concentrations despite higher daily doses.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Weerdenburg H, Walker H, Curtis N, et al. Posaconazole in paediatric malignancy and haematopoietic stem cell transplant: dosing to achieve therapeutic concentration. J Antimicrob Chemother. 2024. PMID: 38637310. doi:10.1093/jac/dkae099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。